ClearSight NextGen1 Study
← catalyst calendarSponsored by Becton, Dickinson and Company (industry) · BDX — their whole pipeline →.
Phase
Not applicable
Status
Completed
Study type
Interventional
Design
Na · None · Other
Enrollment
35actual
Sites
1
Country
United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-16 | actual | When the study began enrolling |
| Primary completion | 2026-03-05 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-05 | actual | The whole study's end, after follow-up |
| First posted | 2026-01-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Blood Pressure
Intervention
- Device: ClearSight NextGen system
Primary outcome
what the primary-completion date above is the date OFData Collection for Development of ClearSight NextGen System
measured Monitoring during surgery, for up to approximately 4 hours.
Permalink · BDX's whole pipeline · Catalyst calendar · Every registered study · What changed